CVS Health(US:CVS) 智通财经网·2025-05-01 14:15Core Viewpoint - CVS Health announced its exit from the individual health insurance market under the Affordable Care Act (ACA) by 2026, primarily due to anticipated losses in the business segment for the 2025 insurance year [1][2] Group 1: Financial Performance - CVS's health insurance segment, "Health Benefits," reported a revenue increase of approximately 8% year-over-year, reaching $34.8 billion, exceeding market expectations of $33.2 billion [1] - The company's total revenue for the quarter was $94.6 billion, surpassing market expectations by $1.2 billion [2] - Adjusted earnings per share (EPS) increased by about 72% year-over-year to $2.25, exceeding market expectations by $0.58 [2] Group 2: Business Segment Highlights - Aetna, CVS's insurance subsidiary, will fully terminate operations in the ACA market by 2026, with a reserve of $448 million set aside for premium losses in the individual insurance product line [1] - The Medicare segment showed improved profitability, with the medical loss ratio decreasing from 90.4% in the previous year to 87.3% [1] - CVS Caremark, the pharmacy benefits management division, achieved $43.5 billion in revenue, an 8% year-over-year increase, driven by optimized drug mix and rising brand drug prices [2] Group 3: Strategic Initiatives - CVS Caremark announced a partnership with Danish pharmaceutical giant Novo Nordisk to enhance the accessibility of its weight management drug Wegovy, prioritizing it in its insurance plans starting July 1 [2] - The company raised its adjusted EPS guidance for 2025 to a range of $6.00 to $6.20, above the previous forecast of $5.75 to $6.00 and higher than the market consensus of $5.91 [2]